Morishita K, Kusajima K, Inoue S, Kuroki M, Komatsu S
Department of Surgery (Section II), Sapporo Medical College, Japan.
Kyobu Geka. 1993 Jan;46(1):9-12.
Forty-eight patients were evaluated. These cases were classified to stage I in 17, stage II in 11, stage III in 13, and stage IV in 7 by Masaoka staging. In 43, a complete resection was performed and in 5, an incomplete resection was carried out. Twelve patients between stage III and IV received postoperative radiotherapy because of incomplete resection and advanced invasive case (defined as high-risk group). Survival at 10 years was 55% for patients who were in high-risk group. This result was disappointed because survival was low in spite of surgical resection combined with postoperative radiation. From that reason, more concentrated therapy might be necessary with not only enlargement of radiation field but also chemotherapy for vascular invasive thymoma in addition to resection.
对48例患者进行了评估。根据Masaoka分期，这些病例中17例为I期，11例为II期，13例为III期，7例为IV期。43例行根治性切除，5例行非根治性切除。III期和IV期的12例患者因切除不彻底和侵袭性强（定义为高危组）而接受了术后放疗。高危组患者的10年生存率为55%。这一结果令人失望，因为尽管手术切除联合术后放疗，但生存率仍较低。因此，除了手术切除外，对于血管侵袭性胸腺瘤，可能需要更集中的治疗，不仅要扩大放疗范围，还要进行化疗。
